Information Provided By:
Fly News Breaks for February 11, 2020
Feb 11, 2020 | 09:16 EDT
SVB Leerink analyst Geoffrey Porges initiated coverage of Sanofi with a Market Perform rating and EUR 105 price target, $58 for the ADR. The analyst notes that his estimates for Sanofi are modestly above recent consensus for the company's total revenue and 1%-2% above consensus for EPS through 2022. Porges has also updated his market forecast for Dupixent to incorporate the many secondary indications now in Phase III. On the other hand, his estimates for other important elements of Sanofi's portfolio are below consensus and offset the "exciting potential" of Sanofi's share of the value of Dupixent.
News For SNY From the Last 2 Days
Jun 5, 2020 | 14:11 EDT
Preliminary research involving 19 patients shows signs that AstraZeneca's (AZN) blood cancer drug Calquence may help hospitalized COVID-19 patients get through the worst of the disease, Reuters reported, citing results in a paper co-authored by the drugmaker's head of oncology research. The executive, Jose Baselga, told Reuters: "These patients were in a very unstable situation, they would have had a dire prognosis ... Within one to three days the majority of these patients got better in terms of ventilation and oxygen needs." Other autoimmune disease drugs that are being tested for their ability to combat the over-reaction of the immune system, known as "cytokine storm," that is seen in severe COVID-19 cases include Regeneron (REGN) and Sanofi's (SNY) Kevzara, Roche's (RHHBY) Actemra and Morphosys (MOR) and GlaxoSmithKline's (GSK) otilimab, the report noted. Reference Link